K
Klaus Dembowsky
Researcher at Bayer
Publications - 65
Citations - 2099
Klaus Dembowsky is an academic researcher from Bayer. The author has contributed to research in topics: Alkyl & Pyrazolopyridine. The author has an hindex of 21, co-authored 63 publications receiving 2044 citations. Previous affiliations of Klaus Dembowsky include Bayer Corporation & Bayer HealthCare Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
NO-independent regulatory site on soluble guanylate cyclase
Johannes-Peter Stasch,Eva Maria Becker,Cristina Alonso-Alija,Heiner Apeler,Klaus Dembowsky,Achim Feurer,Rupert Gerzer,Torsten Minuth,Elisabeth Perzborn,Ulrich Pleiß,Henning Schröder,Werner Schroeder,Elke Stahl,Wolfram Steinke,Alexander Straub,Matthias Schramm +15 more
TL;DR: A pyrazolopyridine is presented that potently stimulates sGC through this site by a mechanism that is independent of NO, which results in antiplatelet activity, a strong decrease in blood pressure and an increase in survival in a low-NO rat model of hypertension, and may offer an approach for treating cardiovascular diseases.
Journal ArticleDOI
NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle
Johannes-Peter Stasch,Peter Schmidt,Cristina Alonso-Alija,Heiner Apeler,Klaus Dembowsky,Michael Haerter,Markus Heil,Torsten Minuth,Elisabeth Perzborn,Ulrich Pleiss,Matthias Schramm,Werner Schroeder,Henning Schröder,Elke Stahl,Wolfram Steinke,Frank Wunder +15 more
TL;DR: A novel type of sGC activator which activates the enzyme even after it has been oxidized by the sGC inhibitor ODQ or rendered haem deficient is identified and may offer a new approach for treating cardiovascular diseases.
Patent
Novel dicarboxylic acid derivatives with pharmaceutical properties
Cristina Alonso-Alija,Markus Heil,Dietmar Flubacher,Paul Naab,Johannes-Peter Stasch,Frank Wunder,Klaus Dembowsky,Elisabeth Perzborn,Elke Stahl +8 more
TL;DR: In this paper, the use of compounds of formula (I) and their salts and stereoisomers for producing medicaments used in the treatment of cardiovascular diseases was described, which relates to the use
Journal ArticleDOI
Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies
Johannes-Peter Stasch,Cristina Alonso-Alija,Heiner Apeler,Klaus Dembowsky,Achim Feurer,Torsten Minuth,Elisabeth Perzborn,Matthias Schramm,Alexander Straub +8 more
TL;DR: The results suggest that BAY 41‐8543 is on the one hand an invaluable tool for studying sGC signaling in vitro and on the other hand its unique profile may offer a novel approach for treating cardiovascular diseases.
Journal ArticleDOI
Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies.
TL;DR: The overall beneficial effects of BAY 41‐8543 manifested as both antiplatelet effect and vasodilatation were reflected in a significant reduction in mortality and suggests that this compound has the potential to be an important research tool for in vivo investigations in the sGC/cGMP field.